Association of Breast Cancer Molecular Subtypes With Patterns of Skeletal Metastases on Bone Scintigraphy
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- Sohag University
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- Presence of skeletal metastases on Tc-99m MDP whole-body bone scintigraphy.
Study Overview
Brief Summary
The goal of this observational study is to evaluate the association between different molecular subtypes of breast cancer and their specific patterns of skeletal metastases on Technetium-99m MDP bone scintigraphy.
The study will include adult male and female patients aged 18 to 80 years with histopathologically confirmed breast cancer who are referred for whole-body bone scintigraphy.
The main questions it aims to answer are:
- What is the frequency and pattern of skeletal metastases across different breast cancer molecular subtypes (Luminal A, Luminal B, HER2-enriched, and Triple-Negative) on bone scintigraphy?
- How do nuclear medicine scintigraphic findings correlate with tumor biomarker profiles? Researchers will compare imaging patterns among the different molecular subtype groups to determine if specific biomarker profiles correlate with distinct bone metastatic behaviors.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Cross Sectional
Eligibility Criteria
- Ages
- 18 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients of both sexes (females and males) with a confirmed histopathological diagnosis of breast cancer, including all major histological types: Invasive Ductal Carcinoma (IDC), Invasive Lobular Carcinoma (ILC), other mixed or less common epithelial variants.
- •Patient's age ranging from 18 to 80 years.
- •Available immunohistochemical (IHC) profiles from the primary breast tumor biopsy or surgery, covering all molecular subtypes including; Luminal A: (ER-positive, PR-positive, HER2-negative, and low Ki-67 index). Luminal B: (ER-positive, PR-variable, HER2-variable "either positive or negative", and high Ki-67 index). HER2-enriched: (ER-negative, PR-negative, and HER2-positive). Triple-Negative breast cancer (TNBC): (no ER, PR or HER2 expression).
- •Patients referred for bone scintigraphy as part of initial staging, follow-up, or due to clinical suspicion of bone metastasis.
Exclusion Criteria
- •Patients with other primary malignancies (to avoid confusion regarding the origin of bone metastases).
- •Patients with incomplete medical records or unavailable immunohistochemical data.
- •Pregnant female patients.
- •Patients aged under 18 years old.
Outcomes
Primary Outcomes
Presence of skeletal metastases on Tc-99m MDP whole-body bone scintigraphy.
Time Frame: Baseline
Number of participants with skeletal metastases detected by Tc-99m MDP whole-body bone scintigraphy according to breast cancer molecular subtype.
Anatomical distribution of skeletal metastases.
Time Frame: Baseline
Anatomical distribution of skeletal metastases (axial skeleton, appendicular skeleton or mixed) according to breast cancer molecular subtype.
Secondary Outcomes
No secondary outcomes reported
Investigators
Reham Soltan Mohamed
Resident Physician
Sohag University